NASDAQ:ODTX

Odyssey Therapeutics (ODTX) Stock Price, News & Analysis

$19.36 +0.22 (+1.15%)
As of 04:00 PM Eastern

About Odyssey Therapeutics Stock (NASDAQ:ODTX)

Advanced

Key Stats

Today's Range
$18.57
▼
$19.67
50-Day Range
$16.60
▼
$26.97
52-Week Range
$15.10
▼
$29.05
Volume
340,246 shs
Average Volume
317,781 shs
Market Capitalization
$930.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.67
Consensus Rating
Moderate Buy

Company Overview

Odyssey Therapeutics is a biotechnology company focused on discovering and developing medicines for inflammatory and autoimmune diseases. Its research centers on the immune system and biological pathways that may be targeted to address these conditions.

Founded in 2021, the company uses drug-discovery capabilities to identify and advance potential therapies. Its business is research and development rather than the sale of marketed medicines.

Odyssey is based in the United States. As a research-focused biotechnology company, its activities are centered on developing potential treatments rather than serving patients through a broad commercial product operation.

AI Generated. May Contain Errors.

Odyssey Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

ODTX MarketRank™: 
2.58476821192 of 5 stars

Odyssey Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 516th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Odyssey Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Odyssey Therapeutics has a consensus price target of $34.67, representing about 79.1% upside from its current price of $19.36.

  • Amount of Analyst Coverage

    Odyssey Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Odyssey Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Odyssey Therapeutics are expected to grow in the coming year, from ($6.02) to ($4.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Odyssey Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Odyssey Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    6.97% of the float of Odyssey Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Odyssey Therapeutics has a short interest ratio ("days to cover") of 15.43, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Odyssey Therapeutics has recently increased by 2.01%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Odyssey Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Odyssey Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Odyssey Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Odyssey Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for ODTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Odyssey Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive ODTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Odyssey Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ODTX Stock News Headlines

What is HC Wainwright's Estimate for ODTX FY2026 Earnings?
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
What is HC Wainwright's Forecast for ODTX Q1 Earnings?
Odyssey Therapeutics: Q3 earnings snapshot
See More Headlines

ODTX Stock Analysis - Frequently Asked Questions

Odyssey Therapeutics' stock was trading at $17.45 on May 11, 2026. Since then, ODTX shares have increased by 10.9% and is now trading at $19.36.

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) announced its quarterly earnings results on Wednesday, June, 17th. The company reported ($6.77) earnings per share for the quarter, missing the consensus estimate of ($1.31) by $5.46.

Odyssey Therapeutics (ODTX) raised $264 million in an initial public offering on Friday, May 8th 2026. The company issued 15,500,000 shares at a price of $16.00-$18.00 per share.

Odyssey Therapeutics's lock-up period expired on Wednesday, November 4th. Odyssey Therapeutics had issued 15,500,000 shares in its public offering on May 8th. The total size of the offering was $279,000,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Top institutional investors of Odyssey Therapeutics include State Street Corp (0.64%), Marshall Wace LLP (0.62%), Aberdeen Group plc (0.36%) and Russell Investments Group Ltd.. Insiders that own company stock include Tpg Gp A, Llc, Dimension Capital Ii, LP, Nan (Ln) Li, Sr One Capital Management, Llc, Jeffrey M Leiden, Jason Haas and Shelley Chu.
View institutional ownership trends
.

Shares of ODTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/05/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ODTX
CIK
1882782
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$42.00
Low Price Target
$27.00
Potential Upside/Downside
+79.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.94
Quick Ratio
12.94

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.82 per share
Price / Book
2.48

Miscellaneous

Outstanding Shares
48,070,000
Free Float
N/A
Market Cap
$930.64 million
Optionable
N/A
Beta
N/A
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:ODTX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners